1. Home
  2. MDWD vs SJT Comparison

MDWD vs SJT Comparison

Compare MDWD & SJT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • SJT
  • Stock Information
  • Founded
  • MDWD 2000
  • SJT 1980
  • Country
  • MDWD Israel
  • SJT United States
  • Employees
  • MDWD N/A
  • SJT N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • SJT Oil & Gas Production
  • Sector
  • MDWD Health Care
  • SJT Energy
  • Exchange
  • MDWD Nasdaq
  • SJT Nasdaq
  • Market Cap
  • MDWD 184.8M
  • SJT 212.1M
  • IPO Year
  • MDWD 2014
  • SJT N/A
  • Fundamental
  • Price
  • MDWD $19.45
  • SJT $4.06
  • Analyst Decision
  • MDWD Strong Buy
  • SJT
  • Analyst Count
  • MDWD 1
  • SJT 0
  • Target Price
  • MDWD $25.00
  • SJT N/A
  • AVG Volume (30 Days)
  • MDWD 78.0K
  • SJT 230.2K
  • Earning Date
  • MDWD 03-20-2025
  • SJT 11-14-2024
  • Dividend Yield
  • MDWD N/A
  • SJT 2.33%
  • EPS Growth
  • MDWD N/A
  • SJT N/A
  • EPS
  • MDWD N/A
  • SJT 0.19
  • Revenue
  • MDWD $19,720,000.00
  • SJT $11,031,594.00
  • Revenue This Year
  • MDWD $10.15
  • SJT N/A
  • Revenue Next Year
  • MDWD $25.62
  • SJT N/A
  • P/E Ratio
  • MDWD N/A
  • SJT $21.16
  • Revenue Growth
  • MDWD N/A
  • SJT N/A
  • 52 Week Low
  • MDWD $11.04
  • SJT $3.21
  • 52 Week High
  • MDWD $24.00
  • SJT $5.81
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 55.03
  • SJT 42.74
  • Support Level
  • MDWD $19.59
  • SJT $4.12
  • Resistance Level
  • MDWD $20.62
  • SJT $4.30
  • Average True Range (ATR)
  • MDWD 0.83
  • SJT 0.19
  • MACD
  • MDWD 0.02
  • SJT -0.04
  • Stochastic Oscillator
  • MDWD 54.60
  • SJT 1.28

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

Share on Social Networks: